Debjeet Sur

Dr. Debjeet Sur

Pharmacy, Amity University Kolkata, Kolkata, India
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
Debjeet SurDebjeet Sur
Debjeet Sur
SBSarmin Banu
Sarmin Banu
Metabolic diseases such as type 2 diabetes mellitus are usually associated with meta-inflammation. β-cell failure is a marked feature observed in the pathogenesis of type 2 diabetes mellitus. Type 2 diabetes mellitus (T2DM) is a heterogeneous situation that is accompanied by not only defective insulin secretion but also peripheral insulin resistance. β-cells are the primary organ for insulin secretion; hence, it is crucial to maintain a significant β-cell mass in response to a variety of changes. Insulin resistance is a chief cause of T2DM, leading to increased free fatty acid (FFA) levels, which in turn elevates β-cell mass and insulin secretion as compensation for insulin insensitivity. It has recently been established that amplified numbers of innate immune cells, cytokines, and chemokines result in detrimental effects on islets in chronic conditions. Macrophage migration inhibitory factor (MIF) is the lymphokine that prevents arbitrary migration of macrophages and assembles macrophages at inflammatory loci. Inflammation is known to trigger monocytes to differentiate into macrophages. Progress of complications associated with type 2 diabetes mellitus, as indicated through recent findings, is also dependent on the buildup of macrophages in tissues vulnerable to diabetic injury. The present article scientifically evaluates the present knowledge concerning the mechanisms of monocyte and macrophage-mediated injury recruitment in complications associated with type 2 diabetes mellitus. It also describes some of the established and experimental therapies that might bring about a reduction in these inflammatory complications. Recent discoveries in the field of drug delivery have facilitated phenotype-specific targeting of macrophages. This review highlights the pathophysiology of type 2 diabetes mellitus, how macrophage induces type 2 diabetes mellitus and potential therapeutics for type 2 diabetes mellitus via macrophage-specific delivery.

21 August 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
OCOishani Chaterjee
Oishani Chaterjee
Debjeet SurDebjeet Sur
Debjeet Sur

9 April 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
SRSusmita Roy
Susmita Roy
MPMehnaz Parveen
Mehnaz Parveen
ABAsis Bala
Asis Bala
Debjeet SurDebjeet Sur
Debjeet Sur

10 March 2022 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
Debjeet SurDebjeet Sur
Debjeet Sur
ADArpan Dutta
Arpan Dutta
CMChaitali Mondal
Chaitali Mondal
ABApurba Banerjee
Apurba Banerjee
PHPallab Kanti Haldar
Pallab Kanti Haldar
ABAsis Bala
Asis Bala

25 March 2024 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
SMSourav Mondal
Sourav Mondal
SSSarthak Saha
Sarthak Saha
Debjeet SurDebjeet Sur
Debjeet Sur
Rheumatoid arthritis (RA) is a persistent autoimmune condition characterized by ongoing inflammation primarily affecting the synovial joint. This inflammation typically arises from an increase in immune cells such as neutrophils, macrophages, and T cells (TC). TC is recognised as a major player in RA pathogenesis. The involvement of HLA-DRB1 and PTPN-2 among RA patients confirms the TC involvement in RA. Metabolism of TC is maintained by various other factors like cytokines, mitochondrial proteins & other metabolites. Different TC subtypes utilise different metabolic pathways like glycolysis, oxidative phosphorylation and fatty acid oxidation for their activation from naive TC (T0). Although all subsets of TC are not deleterious for synovium, some subsets of TC are involved in joint repair using their anti-inflammatory properties. Hence artificially reprogramming of TC subset by interfering with their metabolic status poised a hope in future to design new molecules against RA.

1 June 2023 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
Debjeet SurDebjeet Sur
Debjeet Sur
PSPoulami Sarkar
Poulami Sarkar
SBSharmin Banu
Sharmin Banu
SBSanchari Bhattacharya
Sanchari Bhattacharya
ABAsis Bala
Asis Bala
Alzheimer’s disease (AD) is the most common type of dementia that affects the elderly around the world. Chronic type 2 diabetes (T2DM) has been proven to be closely related to neurodegeneration, especially AD. T2DM is characterized by the cell's failure to take up insulin as well as chronic hyperglycemia. In the central nervous system, insulin plays vital regulatory roles, while in chronic hyperglycemia, it leads to the formation and accumulation of advanced glycation end products (AGEs). Inflammation plays a crucial role in development of insulin resistance in AD and T2DM. The microtubule-related protein tau is involved in the pathogenesis of several neurological diseases known as tauopathies, and is found to be abnormally hyperphosphorylated in AD and accumulated in neurons. Chronic neuroinflammation causes the breakdown of the blood-brain barrier (BBB) observed in tauopathies. The development of pro-inflammatory signaling molecules, such as cytokines, chemokines from glial cells, neurons and endothelial cells, decides the structural integrity of BBB and immune cell migration into the brain. This review highlights the use of antidiabetic compounds as promising therapeutics for AD, and also describes several new pathological molecular mechanisms associated with diabetes that increase AD pathogenesis.